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efuroxime axetil (Ceftin(R), Glaxo Wellcome,
Research Triangle Park, NC) is the oral pro-
drug formulation of the injectable antibiotic cefu-
roxime sodium. It has essentially the same antibac-
terial activity as its parent moiety, making cefurox-
ime the only second-generation cephalosporin with
both an intravenous and oral formulation.
STRUCTURE AND DERIVATION
Cefuroxime axetil is the 1-acetoxyethyl ester of ce-
furoxime. The axetil salt renders the molecule
more lipophilic, thus allowing enhanced oral ab-
sorption. Once cefuroxime axetil reaches the in-
testinal mucosa and portal blood flow it rapidly un-
dergoes de-esterification to yield the active parent
compound cefuroxime.
MECHANISM OF ACTION
Cefuroxime axetil is a second-generation cephalo-
sporin that contains the classic [3-1actam ring struc-
ture. Bactericidal activity in vivo is resultant of its
binding to essential target proteins, termed the
penicillin-binding proteins, which are located in
the bacterial cell wall. Inhibition of these proteins
leads to bacterial cell wall elongation and leakage,
thus the bacteria are unable to divide and mature, z
PHARMACOKINETICS
Cefuroxime axetil is available as a tablet and a fla-
vored suspension. Although the tablets have un-
dergone three product reformulations in an attempt
to standardize absorption, the bioavailability issues
have been resolved with the currently marketed
tablet. Cefuroxime axetil is converted to the active
moiety, cefuroxime, in less than 3 min once ab-
sorbed. Due to the rapid conversion it is not pos-
sible to detect cefuroxime axetil in the systemic
circulation. Peak serum concentration achieved af-
ter a single 250 mg dose in the fed state is 4.7
mcg/ml and is reached after 2.1 h post-ingestion.
3
The administration of food with cefuroxime axetil
substantially increases its absorption. ,4,s The bio-
availability was shown to increase from 36% to 52%
when a 5;00 mg dose was taken in a fasting state
compared to being administered after food.s The
mechanism for this increased bioavailability is not
completely understood. It has been proposed that
food-induced cholecystokinin release which causes
the gall bladder to contract and release bile may be
responsible for improving absorption.
6
Cefuroxime axetil, as cefuroxime, is approxi-
mately 30% protein bound and has a volume of
distribution of about 17 1. 7 Distribution of this an-
tibiotic into body fluids and tissues is variable,
however, it does penetrate well (35-90%) into the
tonsil tissue, sinus tissue, and bronchial mucosa.8
Once de-esterified and released into systemic
circulation, cefuroxime is not metabolized further,
but is eliminated unchanged in the urine. In pa-
tients with normal renal function, the plasma elimi-
nation half-life after a dose of 500 mg of cefuroxime
is 1.4. h. The elimination half-life increases as the
renal function declines. In patients with creatinine
clearances <10 ml/min the elimination half-life ex-
tends to approximately 16.8 h.9 Based on these re-
suits, it is recommended that the dosing interval be
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TABLE I. Dosage guidelines for renal dysfunction
Estimated creatinine
clearance Recommended dosage
30-49 ml/min/I.73 m
10-29 ml/min/I.73 m
< 10 ml/min/I.73 m
Standard individual dose
given every 12 h
Standard individual dose
given every 24 h
Standard individual dose
given every 48 h
aAdapted from Konishi et al.
extended in patients with renal dysfunction (see
Table 1).
SIDE EFFECTS AND INTERACTIONS
Cefuroxime axetil is associated with a low inci-
dence of adverse effects and is generally well tol-
erated. The most frequently reported adyerse ef-
fects are primarily gastrointestinal in nature, in-
cluding diarrhea/loose stools (3.7%), nausea (2.6%),
and vomiting (2.6%). 1<11 In clinical trials com-
prised of large cohorts of patients (n 912) using
multiple doses of cefuroximc axetil, only 2.2% of
patients discontinued treatment due to adverse re-
actions. Of those who discontinued treatment, 85%
did so because of gastrointestinal complaints.1
Other occasionally reported adverse events as-
sociated with cefuroxime axetil include antibiotic-
associated colitis and liver function abnormalities.
Hypersensitivity reactions including Stevens-
Johnson syndrome, erythema multiforme, and toxic
epidermal necrolysis have been reported rarely
during post-marketing surveillance. 1,11
Concurrent use of cefuroxime with probenecid
may increase the serum concentration of cefurox-
ime. Use with warfarin may increase the hypopro-
thrombotic effect of the anticoagulant; therefore,
closer monitoring of the patient’s international nor-
malized ratio during cefuroxime therapy is recom-
mended.1
SPECTRUM OF ANTIMICROBIAL ACTIVITY
Cefuroxime axetil has a wide spectrum of bacteri-
cidal activity both in vivo and in vitro against many
gram-positive bacteria, some gram-negative bacte-
ria, and few anaerobic bacteria. It even covers those
strains that produce 13-1actamases.
lz It is highly ef-
fective against many of the common respiratory
pathogens including Streptococcus pneumoniae, Hae-
mophilus influenzae, and Moraxdla catarrhalis. It is
one of the few oral cephalosporins with some ac-
tivity against isolates of S. pneumoniae that are in-
termediately resistant to penicillin.
13 It also has
good activity against the pathogens that lead to
skin and soft tissue infections, including methicil-
lin-sensitive staphylococci and S. pyogenes. The
most frequently encountered urinary tract infection
pathogens, Escherichia coli, Proteus mirabilis, and
Klebsidla pneumoniae, are also susceptible to cefu-
roxime axetil. Cefuroxime axetil has coverage for
both the penicillinase-positive and -negative
strains of Neisseria gonorrhea, and thus is an alterna-
tive choice for uncomplicated gonorrhea. It has ac-
tivity against Borrelia burgdorferi, the bacteria re-
sponsible for Lyme disease, and some anaerobic
bacteria such as Peptococcus species. Most strains of
Clostridium difficile and Bacteroides fragilis are resis-
tant, and therefore render this antibiotic a poor
choice for most obstetric and gynecological surger-
ies.lO, 14
Pseudomonas species, Campylobacter species, Ad-
netobacter calcoaceticus, most strains of Serratia
species, Proteus vulgaris, and certain strains of
terococci are resistant to therapy with cefuroxime
axetil.1 Resistance is being reported for some nos-
ocomial isolates of Enterobacteriaceae, primarily K.
pneumoniae and E. coli. This is due to bacterial pro-
duction of novel plasmid-mediated 13-1actamases.
is
CLINICAL APPLICATIONS
Multiple clinical trials have investigated the thera-
peutic efficacy of cefuroxime axetil in upper and
lower respiratory tract infections, uncomplicated
urinary tract infections, skin and soft tissue infec-
tions, uncomplicated gonorrhea, and early stage
Lyme disease. Although cefuroxime axetil has la-
beled indications for all of the previously men-
tioned infections,1 it is generally not the preferred
antibiotic for initial treatment since equally effica-
cious and less expensive options are available. For
general use in obstetrics and gynecological infec-
tions, cefuroxime axetil may be considered a useful
alternative for treating uncomplicated gonorrhea
and urinary tract infections (UTIs). It is considered
safe to use in pregnancy (pregnancy category B). 16
Uncomplicated Gonorrhea
For treatment of uncomplicated gonorrhea, the
Centers for Disease Control and Prevention (CDC)
recommends ceftriaxone 125 mg IM once plus a 7
212 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGYCEFUROXIME AXETIL (CEFTIN (R) LEDER AND CARSON
day course of doxycycline for the presumptive con-
current infection with Chlamydia. This regimen has
a greater than 95% cure rate for anal and genital
infections while also achieving cure rates of->90%
for pharyngeal infections. Another advantage for
ceftriaxone is it may also abort incubating syphilis,
a concern when treatment is not accompanied by a
7 day course of doxycycline. Cefuroxime axetil g
orally as a single dose is considered an alternative
regimen. However, a single dose of this shorter-
acting cephalosporin will not cover incubating
syphilis nor C. trachomatis. 17 Clinical trials con-
ducted using 1-1.5 g single doses of cefuroxime
axetil either alone or in combination with proben-
ecid have produced cure rates of 96-100% in
gonococcal genitorectal infections in both men and
women. 18-z4 However, these high cure rates were
not achieved in patients with pharyngeal gonococ-
cal infections,z In comparative trials vs. amoxicil-
lin plus probenecid, cefuroxime axetil was shown
to be equally effective. 19-z There have been no
comparative trials between cefuroxime axetil and
ceftriaxone.
UTIs
The most commonly identified UTI pathogens in-
clude E. coli, K. pneumoniae, and P. mirabilis. Cefu-
roxime axetil has been shown to be effective
against these urinary pathogens, but provides
broader coverage than necessary for most uncom-
plicated UTIs. The antibiotic of choice for the
treatment of acute uncomplicated UTIs is trim-
ethoprim in combination with sulfamethoxazole
(TMP/SMX) or amoxicillin. For patients with an
allergy to these agents, cefuroxime axetil is an ex-
pensive alternative. Several dosing regimens for
treatment of UTIs have proved effective with ce-
furoxime axetil. In one clinical trial in non-
pregnant women, single dose therapy with 1,000
mg resulted in a 88% clinical and bacteriological
cure at week post-therapy,zs A slightly longer 3
day therapy trial with 125 mg twice daily had a
similar efficacy, an 84.8% clinical cure.z6 The more
traditional 7 day therapy 125 mg twice daily re-
suited in a 97% bacteriological cure at 1 week post-
therapy,z7
COST
Table 2 represents the average wholesale price to
the pharmacist for a 7 day supply of selected anti-
TABLE 2. Comparison of cost of commonly
prescribed antibiotics used to treat obstetric and
gynecological infections
AWP cost
Daily for 7 day
Drug dosage supply
b
Amoxicillin
Generic 250 mg q 8 h
Amoxil (R)
Clavulanate potassium
-Augmentin
(R) 500 mg q 12 h
Cefaclor
Generic 250 mg q 8 h
Ceclor(R)
Cefuroxime axetiI-Ceftin (R) 250 mg q 12 h
g x dose
Ceftriaxone-Rocephin (R) 125 mg IM x
Doxycycline-generic 100 mg q 12 h
Trimethoprim-sulfamethoxazole
Generic double-strength
Bactrim DS (R)
Septra DS (R)
tablet q 12 h
$4.41
$4.54
$40.32
$40.90
$46.49
$44.94
$12.84
$12.04
$2.24
$4.76
$17.50
$16.94
aUsual adult dosage recommended by the manufacturer.
bCost tO the pharmacist based on average wholesale price (AWP) list-
ings in Drug Topics Red Book (1996); cost to the patient may be higher.
biotics. These selected antibiotics represent either
first-line choices for therapeutic indications such as
gonorrhea, UTI, and skin/soft tissue infection, or in
the case of cefaclor, have a similar spectrum of ac-
tivity. In most cases, cefuroxime axetil is the more
expensive choice with no increase in efficacy or
safety.
CONCLUSIONS
Cefuroxime axetil is a broad spectrum 13-1actam an-
tibiotic. It has many approved indications, how-
ever, it is considered a second-line alternative. It is
not the drug of choice for any infection, particularly
those encountered in the field of obstetrics and
gynecology. It is safe to use in pregnancy and has a
low adverse effect profile, but due to its excessive
acquisition cost and better therapeutic alternatives,
it should be reserved for select cases.
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